samedan logo
 
 
 
spacer
home > ebr > spring 2003 > live cells as drug discovery tools - high-throughput, high-content screening
PUBLICATIONS
European Biopharmaceutical Review

Live Cells as Drug Discovery Tools - High-Throughput, High-Content Screening

In the drug discovery arena, the better the quality of data, the better the chance of striking 'therapeutic gold'. To bridge the gap from candidate compound to blockbuster drug, the assay should mimic the drug target interactions that occur in a living human cell. Traditional screening practices have been based within the non-cellular environment in order to maximise sample throughput and generate simple one-dimensional data. More recently, the advent of low-throughput, high-content systems have allowed more relevant and complex cell-based assays to be performed. However, cell-based, high-content assays and high-throughput screening need not be mutually exclusive - high-information, high-throughput cell-based technologies are available. A new laser scanning system can provide greater insight into the events occurring at the living cell level and pull low-throughput secondary screening assays into the primary screening stage.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Richard Philpott, Managing Director of Acumen Bioscience Ltd

Dr Richard Philpott is Managing Director of Acumen Bioscience Ltd. Graduating from Imperial College, London, Richard completed a sponsored PhD on Steroid Metabolism at CAMR, Porton Down (UK) in 1986. Subsequently he joined the biotechnology division of Alcan International to lead development projects involving sensors, novel separations media and devices.

Following acquisition by Whatman, he transferred to their Maidstone (UK) headquarters as Director of R&D. He joined The Technology Partnership (TTP Group) in March 2001 to lead the formation of Acumen Bioscience Ltd, a wholly owned subsidiary commercialising technologies developed within TTP for drug screening.

spacer
Dr Richard Philpott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement